ERBB2 and breast carcinoma: For similar reasons, the ErbB2 monoclonal antibodies (Trastuzumab) that are used to treat Her2+ breast cancer, or the molecules (e.g., recombinant NRG1β and anti-ErbB4 antibodies) that are currently in development for heart disease and cancer might not be useful for neurodevelopmental disorders74,75.